Skip to content

Trial Summary

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Acronym:

ZYMEWORKS HER2

ACTRN/NCT /ethics:

NCT03821233

Scientific title:

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Sponsor / Cooperative group:

Zymeworks Inc

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Advanced, Metastatic or Widespread
Anticipated Start Date2019-04-15
Anticipated End Date2025-08-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting